Laser‐evoked potentials as a tool for assessing the efficacy of antinociceptive drugs

Truini, Andrea; Panuccio, Gabriella; Galeotti, F.; Maluccio, Maria Rosaria; Sartucci, Ferdinando; Avoli, Massimo; Cruccu, G.

doi:10.1016/j.ejpain.2009.05.001

Cited by 73 publications

(61 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Electrostimulation is known to increase conduction velocity and decrease electroexcitability threshold [3]. LIP approach provides the possibility of unbiased assessment of the level and peculiarities of the effects of various factors, both pharmacological [4] and physical, which was demonstrated in our study.…”

Section: Resultssupporting

confidence: 59%

Changes in Parameters of Laser-Induced Potentials After Transcutaneous Electroneurostimulation

Timofeeva

Arkov

et al. 2011

Bull Exp Biol Med

View full text Add to dashboard Cite

Changes in nerve conduction after 10-min electroneurostimulation of the posterior surface of the neck were studied. Changes in the parameters of laser-induced potentials obtained during stimulation of C7 dermatome on hands and posterior surface of the neck were found. Decrease in the amplitude and shortening of the component latency were shown. Method of laser-induced potentials was concluded to provide unbiased estimation of the level and peculiarities of analgesic effects of physical factors.

show abstract

Section: Resultssupporting

confidence: 59%

Changes in Parameters of Laser-Induced Potentials After Transcutaneous Electroneurostimulation

Timofeeva

Arkov

et al. 2011

Bull Exp Biol Med

View full text Add to dashboard Cite

show abstract

“…The exclusion criteria were scholar age of less than 8 years and any peripheral or central nervous system (CNS) diseases, including spinal cord diseases and radiculopathies, psychiatric disease, diabetes, active and/or positive history for thyroid insufficiency, renal failure, autoimmune diseases, inflammatory arthritis, systemic connective tissue disease, present or previous history of cancer, as well as use of drugs acting on the CNS or chronic opioid therapy. Patients taking analgesics were instructed to avoid analgesic use 24 h prior to the laser evoked potentials examination in order to avoid any effect on LEPs amplitudes [22]. Psychiatric disorders were defined according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV).…”

Section: Methodsmentioning

confidence: 99%

Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials

Tommaso

Ricci

Libro

et al. 2017

Pain Research and Treatment

View full text Add to dashboard Cite

Background A dysfunction of pain processing at central and peripheral levels was reported in fibromyalgia (FM). We aimed to correlate laser evoked potentials (LEPs), Sympathetic Skin Response (SSR), and clinical features in FM patients. Methods Fifty FM patients and 30 age-matched controls underwent LEPs and SSR by the right hand and foot. The clinical evaluation included FM disability (FIQ) and severity scores (WPI), anxiety (SAS) and depression (SDS) scales, and questionnaires for neuropathic pain (DN4). Results The LEP P2 latency and amplitude and the SSR latency were increased in FM group. This latter feature was more evident in anxious patients. The LEPs habituation was reduced in FM patients and correlated to pain severity scores. In a significant number of patients (32%) with higher DN4 and FIQ scores, SSR or LEP responses were absent. Conclusions LEPs and SSR might contribute to clarifying the peripheral and central nervous system involvement in FM patients.

show abstract

“…40 To find out whether LEPs also provide a useful neurophysiological tool for assessing antinociceptive drug efficacy, the group of Truini measured, in a double-blind, placebo-controlled study, changes induced by tramadol on LEPs, in 12 healthy subjects. 88 They found that tramadol decreased LEPs amplitude, whereas placebo left LEPs unaltered. The opioid antagonist naloxone partially reversed the tramadol-induced LEP amplitude decrease.…”

Section: 282987mentioning

confidence: 98%

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

et al. 2011

View full text Add to dashboard Cite

Neuropathic cancer pain (NCP), commonly encountered in clinical practice, may be cancer-related, namely resulting from nervous system tumor invasion, surgical nerve damage during tumor removal, radiation-induced nerve damage and chemotherapy-related neuropathy, or may be of benign origin, unrelated to cancer. A neuropathic component is evident in about 1/3 of cancer pain cases.Although from a pathophysiological perspective NCP may differ from chronic neuropathic pain (NP), such as noncancer-related pain, clinical practice, and limited publications have shown that these two pain entities may share some treatment modalities. For example, co-analgesics have been well integrated into cancer pain-management strategies and are often used as First-Line options for the treatment of NCP. These drugs, including antidepressants and anticonvulsants, are recommended by evidence-based guidelines, whereas, others such as lidocaine patch 5%, are supported by randomized, controlled, clinical data and are included in guidelines for restricted conditions treatment. The vast majority of these drugs have already been proven useful in the management of benign NP syndromes. Treatment decisions for patients with NP can be difficult. The intrinsic difficulties in performing randomized controlled trials in cancer pain have traditionally justified the acceptance of drugs already known to be effective in benign NP for the management of malignant NP, despite the lack of relevant high quality data. Interest in NCP mechanisms and pharmacotherapy has increased, resulting in significant mechanism-based treatment advances for the future. In this comprehensive review, we present the latest knowledge regarding NCP pharmacological management. n INTRODUCTIONFollowing EFIC's (European Federation of IASP Chapters) declaration in 2001, pain is not a symptom but a disease in its own right, necessitating appropriate treatment. The word pain usually refers to a discrete sensory experience, triggered by an identifiable set of ''painful'' stimuli, acting on a unique or stable ''pain'' pathway and eliciting an invariant sensation. However, pain, and particularly neuropathic pain (NP) can also exist as a diverse group of complex phenomena of unpleasant and distressing nature. NP encloses numerous complicated neurobiologic constituents and reflects potentially dynamic mechanisms, interacting at multiple neuraxial sites. 1Modern neurobiological techniques have led to tremendous progress in the exploration of pain pathogenetic mechanisms. [2][3][4] Research indicates that pain can be produced in multiple ways, at different locations, co-existing between and across various pathological conditions. 5,6 Novel therapeutic targets have been discovered and are used by the pharmaceutical industry for the construction of highly specific molecules, acting as potential innovative analgesics. Recent targets' application, specific to precise NP mechanisms, will very soon enable treatment to be focused at particular mechanisms, introducing a mechanism-based therap...

show abstract

Laser‐evoked potentials as a tool for assessing the efficacy of antinociceptive drugs

Cited by 73 publications

References 20 publications

Changes in Parameters of Laser-Induced Potentials After Transcutaneous Electroneurostimulation

Changes in Parameters of Laser-Induced Potentials After Transcutaneous Electroneurostimulation

Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

Contact Info

Product

Resources

About